glutathione mutations in sclc patients

glutathione mutations in sclc patients Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation | Cancer & Metabolism RETRACTED ARTICLE: Novel prognostic biomarkers

Name: glutathione mutations in sclc patients Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation | Cancer & Metabolism RETRACTED ARTICLE: Novel prognostic biomarkers
Brand: crisbcreativa.com
SKU: 66077133301
Price: 24.29 USD
Availability: InStock
Rating: 4.2385 (18 reviews)

RETRACTED ARTICLE: Novel prognostic biomarkers in small cell lung cancer reveal mutational signatures, genomic mutations, and immune implications Scientific Reports The changing treatment landscape of EGFR mutant non small cell lung cancer Nature Reviews Clinical Oncology Frontiers Targeting lung cancer: synergistic therapeutic strategy of cuproptosis and immunogenic cell death Oncology Letters Tumor suppressor genes and KRAS G12C inhibitor resistance in non small cell lung cancer: iScience

SKU: 66077133301 · From crisbcreativa.com

4.2

USD24.29 USD47.29

Pay in 4 interest-free payments of $6.07 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Sep 17 - Sep 22

Description

Soboll S, Gruendel S, Harris J, Kolb-Bachofen V, Ketterer B, Sies H (1995) The content of glutathione and glutathione s-transferases and the glutathione peroxidase activity in rat liver nuclei determined by a non-aqueous technique of cell fractionation

USE CASE 02 Biomedical Research Labs 10-vial and 25-vial packs sized for ongoing lab studies

Womens Health (Larchmt) 21 , 285293 (2012)

Men who took beta-sitosterol experienced greater improvements on 2 standardized assessments of prostate/urinary symptoms than men who took a placebo

Kolarow R, Brigadski T, Lessmann V (2007) Postsynaptic secretion of BDNF and NT-3 from hippocampal neurons depends on calcium calmodulin kinase II signaling and proceeds via delayed fusion pore opening